No description available.

Objetivo: Determinar o processo cicatricial e regenerativo da córnea em suas diferentes camadas diante do dano cirúrgico, através da Ceratectomia Fotorrefrativa (PRK) nos terços anteriores ou injúria do complexo Descemetendotélio no terço posterior. Métodos: Córneas de coelhos foram utilizadas a fim de identificar os nervos presentes, evidenciados através da técnica de imuno-histoquímica (IHQ) da acetilcolinesterase (AchE) e expressos numericamente após quantificação automatizada pelo software Image-Pro. Os seguintes grupos foram incluídos nessa análise: remoção do epitélio com e sem Mitomicina (MMC) 0.02%, -9.0D PRK com e sem MMC. O dano e a regeneração dos nervos foram avaliados através da análise dos grupos após 1 dia, 1, 2, 3 e 6 meses. A morfologia e a distribuição dos nervos foram realizadas através do estudo da tubulina Beta-III, um marcador de microtúbulos presentes em neurônios. Na córnea posterior, a fim de identificar a ocorrência de apoptose após a injúria mecânica do endotélio através de uma cânula romba, cortes desse tecido foram avaliados por meio de técnicas de IHQ através do método de fragmentação do DNA por dUTP e deoxinucleotidil terminal transferase (TUNEL) e microscopia de transmissão eletrônica (TEM) após 1 e 4 horas. A ocorrência de fibrose subsequente à lesão da córnea posterior foi avaliada nos grupos submetidos à Descemetorréxis ou à injúria mecânica do endotélio isolado após 1 mês. O estudo imunohistoquímico para actina de músculo liso (alfa-SMA) permitiu identificar a presença de miofibroblastos e a identificação morfológica da membrana de Descemet demonstrada através do Nidogênio-1 (Nid-1), tornando possível, portanto, a discriminação do papel das camadas posteriores no processo cicatricial da córnea. Olhos contralaterais foram incluídos como um grupo controle em todas as análises. Resultados: Na face anterior da córnea, uma menor área do complexo nervoso foi observada um dia após o PRK associado ao uso da MMC (p=0.0009) quandocomparado ao PRK sem o uso da medicação, que não se manteve após um mês (p=0.9). O PRK sem MMC demonstrou uma crescente capacidade regenerativa de seus nervos, que apresentaram valores comparáveis aos pré-operatórios após o terceiro mês. No entanto, tais fibras nervosas apresentaram uma morfologia aberrada mantida até a análise do mês seis. Na face posterior da córnea, apesar da presença de células TUNEL+ após 1 e 4 horas subsequentes ao dano mecânico do endotélio isolado, não houve a expressão de alfa-SMA no estroma posterior após um mês. A integridade estrutural da membrana de Descemet nesse grupo foi confirmada através do Nidogênio-1 (Nid-1), diferentemente do observado após o dano ao complexo Descemet-endotélio, em que houve ampla expressão de alfa-SMA identificando a presença de miofibroblastos e o consequente desenvolvimento de cicatrizes responsáveis pela perda de transparência na córnea. Conclusão: O uso do excimer laser na superfície anterior causou prejuízo à inervação da córnea. Todavia, a capacidade regenerativa das fibras nervosas foi demonstrada ao longo dos meses, apesar da persistência de uma anômala arquitetura e redistribuição dos nervos mesmo após o sexto mês. A MMC revelou uma discreta e precoce propriedade neurotóxica quando combinada ao uso do excimer laser, que não implica perda da segurança a médio/longo prazo do uso dessa droga na concentração e tempos utilizados nesse estudo. No terço posterior da córnea, a membrana de Descemet exibiu um importante papel modulador no processo de desenvolvimento de cicatrizes ou fibrose no estroma profundo. Uma vez lesada, torna constante o influxo de citocinas inflamatórias necessárias para a diferenciação e persistência do miofibroblasto. Tal processo mostrou-se análogo ao papel da membrana basal do epitélio como reguladora do processo de fibrose da córnea anterior / Purpose: To determine the wound-healing cascade and regeneration process of the cornea after surgical injury in its different layers, through Photorefractive Keratectomy (PRK) in the anterior thirds or Descemet-endothelium injury in the posterior third. Methods: Rabbit corneas were used to identify the nerves present in the central area of this tissue by the immunohistochemistry (IHQ) technique of acetylcholinesterase (AchE) and their numerical quantification by Image-Pro software. The following groups were included in this analysis: Removal of epithelium with and without Mitomycin (MMC) 0.02 %, -9.0D PRK with and without MMC. Damage and nerve regeneration were assessed by analyzing the groups after 1 day, 1, 2, 3 and 6 months. The morphology and distribution of nerves along the corneal layers was performed through tubulin beta-III study. At the posterior cornea, to distinguish the occurrence of apoptosis after the mechanical injury of the endothelium through a blunt cannula, sections of this tissue were evaluated by IHQ technique through DNA fragmentation by dUTP and deoxynucleotidyl terminal transferase (TUNEL) and electron transmission microscopy (TEM) after 1 and 4 hours. The occurrence of cornea fibrosis subsequent to posterior corneal injury was evaluated by the group undergoing Descemet membrane surgical removal or by the endothelium mechanical injury after 1 month. The immunohistochemical study for smooth muscle actin (alpha-SMA) allowed the identification of myofibroblasts and the structural integrity of Descemet demonstrated by Nidogen-1 (Nid-1). Thus, making it possible to discriminate the role of the posterior layers during the corneal wound-healing process. Contralateral eyes were included as a control group in all analyzes. Results: At the anterior surface of the cornea, a smaller area of the nervous complex was observed one day after PRK associated with the use of MMC (p = 0.0009) when compared to PRK without the association of the drug, which was not maintained after the first month (p = 0.9). The PRK without MMC demonstrated an increasing regenerative capacity of their nerves, which presented values comparable to preoperative measurements after the third month. However, morphological differences and an aberrant distribution of innervation were persistent. At the corneal posterior surface, despite the presence of TUNEL + cells after 1 and 4 hours subsequent to the mechanical damage of the isolated endothelium, there was no alpha-SMA expression in the posterior stroma after one month. The structural integrity of Descemet\'s membrane in this group was confirmed by Nidogen-1 (Nid-1). Differently from what was observed after damage to the Descemet membrane by it surgical removal, there was a large expression of alpha-SMA identifying the myofibroblasts and the consequent development of scars responsible for the loss of corneal transparency. Conclusion: The excimer laser use on the anterior surface caused destruction to the corneal innervation. However, the regenerative capacity of nerve fibers was demonstrated over the months, despite the persistence of anomalous architecture and redistribution of the corneal nerves that persisted even after six months. MMC exhibited a moderate and early neurotoxic effect when combined with the excimer laser treatment at the concentration and time used in this study At the inferior third of the cornea, Descemet\'s membrane exhibited an important role during the modulation process of scarring or fibrosis in the deep stroma. Once damaged, a constant influx of inflammatory cytokines into the stroma was guaranteed and a differentiation and persistence of the myofibroblast occur. This process has been shown to be analogous to the role of the corneal epithelial basement membrane as a regulator of the anterior cornea fibrosis process

Idarubicin (IDA) and mitomycin C (MC) are clinically effective quinone-containing anticancer agents used in the treatment of several human cancers. Quinone-containing anticancer drugs have the potential to undergo bioreduction by oxidoreductases to reactive species, and thereby exert their cytotoxic effects. In the present study, we investigated, for the first time, the potential of IDA, in comparison to MC, to undergo reductive activation by NADPH-cytochrome P450 reductase (P450R), NADH-cytochrome b5 reductase (b5R) and P450R-cytochrome P4502B4 (CYP2B4) system by performing both in vitro plasmid DNA damage experiments and enzyme assays. In addition, we examined the potential protective effects of some antioxidants against DNA-damaging effects of IDA and MC resulting from their reductive activation. To achieve these goals, we obtained P450R from sheep lung, beef liver and PB-treated rabbit liver microsomes, b5R from beef liver microsomes and CYP2B4 from PB-treated rabbit liver microsomes in highly purified forms. The plasmid DNA damage experiments demonstrated that P450R is capable of effectively reducing IDA to DNA-damaging species. The effective protections provided by antioxidant enzymes, SOD and catalase, as well as scavengers of hydroxyl radical, DMSO and thiourea, revealed that the mechanism of DNA damage by IDA involves the generation of ROS by redox cycling of IDA with P450R under aerobic conditions. The extent of DNA damages by both IDA and MC were found to increase with increasing concentrations of the drug or the enzyme as well as with increasing incubation time. IDA was found to have a greater ability to induce DNA damage at high drug concentrations than MC. The plasmid DNA experiments using b5R, on the other hand, showed that, unlike P450R, b5R was not able to reduce IDA to DNA-damaging reactive species. It was also found that in the presence of b5R and cofactor NADH, MC barely induced DNA strand breaks. All the purified P450Rs reduced IDA at about two-fold higher rate than that of MC as shown by the measurement of drug-induced cofactor consumption. This indicates that IDA may be a more potent cytotoxic drug than MC in terms of the generation of reactive metabolites. The results obtained from enzyme assays confirmed the finding obtained from plasmid DNA experiments that while MC is a very poor substrate for b5R, IDA is not a suitable substrate for this enzyme unlike P450R. The reconstitution experiments carried out under both aerobic and anaerobic conditions using various amounts of CYP2B4, P450R and lipid DLPC revealed that reconstituted CYP2B4 produced about 1.5-fold and 1.4-fold rate enhancements in IDA and MC reduction catalyzed by P450R alone, respectively. The present results also showed that among the tested dietary antioxidants, quercetin, rutin, naringenin, resveratrol and trolox, only quercetin was found to be highly potent in preventing DNA damage by IDA. These results may have some practical implications concerning the potential use of P450R as therapeutic agent on their own in cancer treatment strategies. Selective targeting of tumor cells with purified P450R by newly developed delivery systems such as using polymers, liposomes or antibodies may produce greater reductive activation of bioreductive drugs in tumor cells. Consequently, this strategy has a high potential to increase the efficacy and selectivity of cancer chemotherapy.

19 Dec 2004. / Published through the Information Bridge: DOE Scientific and Technical Information. "IS-T 2695" Qinhua Huang. 12/19/2004. Report is also available in paper and microfiche from NTIS.

Made available in DSpace on 2015-07-22T20:49:23Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-02-24. Added 1 bitstream(s) on 2015-08-11T03:25:35Z : No. of bitstreams: 1 Publico-026a.pdf: 72550 bytes, checksum: afe0787528f227bc8c799cf1cd67fcc7 (MD5). Added 1 bitstream(s) on 2015-08-11T03:25:35Z : No. of bitstreams: 2 Publico-026a.pdf: 72550 bytes, checksum: afe0787528f227bc8c799cf1cd67fcc7 (MD5) Publico-026b.pdf: 2073659 bytes, checksum: b85cc4a971ac414e9e8aa01daa4ad8ed (MD5). Added 1 bitstream(s) on 2015-08-11T03:25:36Z : No. of bitstreams: 3 Publico-026a.pdf: 72550 bytes, checksum: afe0787528f227bc8c799cf1cd67fcc7 (MD5) Publico-026b.pdf: 2073659 bytes, checksum: b85cc4a971ac414e9e8aa01daa4ad8ed (MD5) Publico-026c.pdf: 2083167 bytes, checksum: 806646b87026c136bf8b329233fe315b (MD5). Added 1 bitstream(s) on 2015-08-11T03:25:36Z : No. of bitstreams: 4 Publico-026a.pdf: 72550 bytes, checksum: afe0787528f227bc8c799cf1cd67fcc7 (MD5) Publico-026b.pdf: 2073659 bytes, checksum: b85cc4a971ac414e9e8aa01daa4ad8ed (MD5) Publico-026c.pdf: 2083167 bytes, checksum: 806646b87026c136bf8b329233fe315b (MD5) Publico-026d.pdf: 895113 bytes, checksum: 37de279e78fead2b9aa3c17fd44ab0f0 (MD5) / Objetivos: Comparar os resultados de acuidade visual, refração estática, aberrometria e sensibilidade ao contraste em olhos com miopia moderada submetidos à ceratectomia fotorrefrativa (PRK) com mitomicina C (MMC) ou à ceratomileuse assistida por excimer laser in situ (LASIK) em cirurgias guiadas por frente de onda durante acompanhamento de um ano. Avaliar o aspecto biomicroscópico nos dois grupos durante seguimento. Avaliar subjetivamente percepção de dor, queixas visuais e satisfação com resultado cirúrgico nos dois grupos durante acompanhamento. Analisar índices de microscopia especular nos dois grupos antes e seis meses após cirurgia. Comparar propriedades biomecânicas da córnea nos dois grupos um ano após o procedimento cirúrgico. Métodos: Quarenta e quatro pacientes (88 olhos) com miopia moderada e cálculo de consumo corneano maior que 50 μm na plataforma LADARWave 4000 (Alcon) em ambos os olhos foram selecionados para receber aleatoriamente LASIK em um olho e PRK com aplicação de MMC 0,002% durante um minuto no olho contralateral em cirurgias guiadas por frente de onda. Topografia corneana (EyeSys 2000, EyeSys e Orbscan II, Orbtek/Bausch & Lomb), acuidade visual sem correção (AVSC, tabela Early Treatment Diabetic Retinopaty Study), refração estática, acuidade visual com correção (AVCC), aberrometria (LADARWave 4000), paquimetria ultrassônica corneana central (Sonogage) e exame oftalmológico completo foram realizados no pré-operatório e no seguimento de um, três, seis e doze meses pós-operatório. Sensibilidade ao contraste fotópica e mesópica (Optec 6500, F.A.C.T.; Stereo Optical) com correção foram realizadas nos dois olhos antes da cirurgia e três, seis e doze meses após. Questionário subjetivo de dor foi aplicado no pós-operatório recente, e questionário de sintomas visuais e satisfação com o procedimento em cada olho foi aplicado nas visitas de acompanhamento com um, três, seis e doze meses de pós-operatório. Biomicroscopia de segmento anterior foi realizada no período pós-operatório recente e nas visitas de acompanhamento sempre como último exame do dia (examinador mascarado para procedimento cirúrgico). Microscopia especular (Topcon SP 2000p) foi realizada antes e seis meses após cirurgia. Avaliação biomecânica da córnea (ORA, Reichert) foi realizada um ano após o procedimento cirúrgico. Os testes ANOVA para medidas repetidas e t de student foram utilizados para análise estatística. Resultados: A média de idade dos pacientes do estudo foi de 31,7 anos (variou entre 21 e 54 anos). Não houve diferença significativa entre os grupos antes da cirurgia quanto a AVSC, AVCC, aberrometria, sensibilidade ao contraste ou microscopia especular. O equivalente esférico (EE) médio programado nos olhos que receberam LASIK foi de - 3,99±1,20 dioptrias (D) e de - 3,85±1,12 D nos olhos que receberam PRK com MMC (p>0,05). A profundidade de ablação média foi de 73,09±14,55 μm e 70,70±14,07 μm, no grupo LASIK e no grupo PRK com MMC, respectivamente (p>0,05). Quarenta e dois pacientes (95,5%) completaram um ano de acompanhamento. Os olhos que receberam PRK com MMC apresentaram média de AVSC significativamente superior aos olhos que receberam LASIK com três, seis e doze meses de pós-operatório. A média de AVCC também foi estatisticamente superior no grupo PRK com MMC na visita de um ano de pós-operatório (p<0,05). Não houve diferença estatística entre os grupos quanto ao EE ao longo do acompanhamento. Todos os olhos que receberam PRK com MMC completaram a reepitelização corneana em até cinco dias após o procedimento, e nenhum olho apresentou haze maior que grau 1 (escala de Fantes). Os olhos que receberam LASIK apresentaram valores de aberrações de baixa e alta ordem estatisticamente superiores aos olhos que receberam PRK com MMC durante todo o acompanhamento (p<0.05). Os olhos que receberam PRK com MMC obtiveram desempenho superior no teste de sensibilidade ao contraste em condições fotópicas e mesópicas quando comparados ao grupo LASIK durante seguimento (p<0,05). Até o quinto dia de pós-operatório, o grupo PRK com MMC apresentou índices de dor superiores ao grupo LASIK. O grupo PRK com MMC foi melhor avaliado no questionário subjetivo de queixas visuais e satisfação cirúrgica. Não houve diferença estatística entre os grupos quanto à microscopia especular (p>0,05). Na avaliação biomecânica da córnea, o grupo LASIK apresentou valores de fator de resistência corneana (CRF) e histerese (CH) significativamente superiores ao grupo PRK com MMC (p<0,05). Conclusões: Os olhos que receberam PRK com MMC apresentaram melhores valores de AVSC e AVCC, melhor correção de aberrações de baixa ordem e menores valores de aberrações de alta ordem em relação aos olhos que receberam LASIK. O grupo PRK com MMC também apresentou valores superiores de sensibilidade ao contraste e foi melhor avaliado em questionário subjetivo de satisfação cirúrgica. Não houve presença de haze clinicamente significativo no grupo PRK com MMC. O grupo PRK com MMC apresentou maiores índices de dor no período pósoperatório recente. Não houve diferença entre os índices de microscopia especular nos dois grupos. O grupo LASIK apresentou índices superiores de CRF e CH. / Purpose: To compare visual acuity results, cycloplegic refraction, aberrometry and contrast sensitivity in eyes that underwent photorefractive keratectomy (PRK) with mitomycin C (MMC) or laser in situ keratomileusis (LASIK) for wavefront-guided myopic corrections during one year follow-up. To evaluate slit-lamp microscopy in both groups during follow-up. To evaluate subjective pain, visual complains and satisfaction with visual results in the two groups during follow-up. To analyse specular microscopy values before and six months after surgeries in both groups. To compare biomechanical properties of the cornea in the two groups one year after surgeries. Methods: Forty-four patients (88 eyes) with moderate myopia and an estimated ablation depth greater than 50 μm using the LADARWave 4000 (Alcon Laboratories) platform in both eyes were randomized to receive LASIK in one eye and PRK with application of MMC 0.002% for one minute in the fellow eye in wavefront-guided surgeries. Corneal topography (EyeSys 2000, EyeSys and Orbscan II, Orbtek/Bausch & Lomb), uncorrected visual acuity (UCVA, Early Treatment Diabetic Retinopaty Study table), cycloplegic refraction, best spectacle-corrected visual acuity (BSCVA), aberrometry (LADARWave 4000), central ultrasound corneal pachymetry (Sonogage Inc) and a comprehensive ophthalmologic examination were performed before surgeries and at one, three, six and twelve months postoperative visits. Photopic and mesopic contrast sensitivity (Optec 6500, F.A.C.T.; Stereo Optical Co) with BSCVA was performed in both eyes before surgeries and at three, six and 12 months follow-up. A subjective pain questionnaire was applied at early postoperative visits and another visual complain and satisfaction questionnaire with surgery in each eye was applied one, three, six and twelve months after surgical procedures. Slit-lamp anterior segment microscopy was performed at early postoperative visits and at follow-up visits always as the last examination (blind examiner for surgical procedure). Specular microscopy (Topcon SP 2000p, Topcon) was performed before and six months after surgeries. Biomechanical properties of the cornea (ORA, Reichert) were evaluated one year after surgeries. The tests ANOVA for repeated measures and the student’s t test were used for statistical analyses. Results: The mean age was 31.7 years (range, 21-54 years). There was no statistically significant between-group difference in UCVA, BSCVA, aberrometry, contrast sensitivity or specular microscopy before surgeries. The mean attempted spherical equivalent (SE) was - 3.99±1.20 diopters (D) in LASIK eyes and - 3.85±1.12 D in PRK with MMC eyes (p>0.05). The mean ablation depth was 73.09±14.55 μm and 70.70±14.07 μm in LASIK and PRK with MMC eyes, respectively (p>0.05). Forty-two patients (95.5%) completed one year follow-up. The PRK with MMC eyes presented statistically significant better mean UCVA values than LASIK eyes at three, six and 12 months visits. The mean BSCVA was also statistically significant better in PRK with MMC eyes than in LASIK eyes one year after surgeries (p<0.05). There was no between-groups statistical difference in SE during one year follow-up. All PRK with MMC eyes reepithelialized within five days after surgical procedure and no eye presented more than grade 1 haze (Fantes scale). The LASIK eyes presented statistically significant higher lower and higher order aberrations values than PRK with MMC eyes during follow-up (p<0.05). The PRK with MMC group showed better results in photopic and mesopic contrast sensitivity than LASIK eyes during one year follow-up (p<0.05). Until the fifth postoperative day, PRK with MMC eyes presented higher pain scores than LASIK eyes. PRK with MMC eyes were better rated in terms of subjective visual symptoms and visual satisfaction. There were no statistical differences between the groups in specular microscopy (p>0.05). LASIK eyes showed statistically significant higher corneal resistance factor (CRF) and corneal hysteresis (CH) values than PRK with MMC eyes (p<0.05). Conclusions: The PRK with MMC eyes presented better UCVA, BSCVA, better correction of lower order aberrations and lower higher order aberration values than LASIK eyes. It also showed better contrast sensitivity results and was better rated in terms of visual satisfaction. There was no clinically significant haze in PRK with MMC eyes. The PRK with MMC eyes presented higher pain scores at early postoperative visits. There was no between groups differences in specular microscopy. LASIK eyes presented higher CRF and CH values one year after surgeries. / TEDE / BV UNIFESP: Teses e dissertações

Les pathologies vésicales sont nombreuses et nécessitent la plupart du temps un traitement médicamenteux. Il peut alors être administré par voie intravésicale, augmentant son efficience et limitant les effets indésirables systémiques. Nous nous sommes intéressés à quatre thérapeutiques : l’alun de potassium, le chlorhydrate de lidocaïne, l’hemisuccinate de méthylprednisolone, la mitomycine C et le bacille de Calmette et Guérin (BCG) en application locale directement dans la vessie. La perméabilité de l’aluminium à travers la vessie a été étudiée au travers d’un cas clinique et des expériences ex vivo ont été réalisées pour définir les paramètres de perméabilité et proposer un algorithme de prédiction de la quantité d’aluminium absorbée dans l’organisme après irrigation intravésicale à l’alun de potassium. Cet algorithme dépend du poids du patient, de la durée de l’irrigation et du volume de la solution utilisée en irrigation vésicale. Des études de perméation ont aussi été réalisées pour le chlorhydrate de lidocaïne, l’hemisuccinate de méthylprednisolone, la mitomycine C et le BCG afin de sécuriser l’emploi de ces thérapeutiques par voie intravésicale. Les études réalisées permettent de prédire, selon les caractères physico-chimiques des molécules, la pénétration dans la membrane vésicale. Une nouvelle formulation galénique réalisée à base d’un gel thermosensible a été étudiée pour optimiser les thérapeutiques intravésicales. Des études de perméation ont été faites avec la nouvelle formulation galénique. Pour finir, une culture de cellules cancéreuses urothéliales a été mise au point et un test de viabilité a été réalisé pour la mitomycine C et le BCG / Bladder diseases are numerous and mostly require medication. Drugs can be administered by intravesical route, thereby increasing efficiency and reducing systemic side effects. We are interested in four drugs: potassium alum, lidocaine hydrochloride, methylprednisolone hemisuccinate, mitomycin C and bacillus Calmette- Guérin (BCG). Mathematical modelling of drug transport through bladder wall is proposed considering scarce literature on this route of administration. The permeability of aluminum through bladder wall was studied through a clinical case and ex vivo experiments were performed to propose a simplified algorithm for the calculation of aluminium dose absorbed in patient with impaired renal function as function of volume of 1% alum solution in the bladder, duration of intravesical irrigation and patient body weight. Permeation studies were also conducted for lidocaine hydrochloride, methylprednisolone hemisuccinate, mitomycin C and BCG to secure intravesical administration of these drugs. Practical outcome of this study could drive compounding optimisation towards improvement of safety and efficacy in patient undergoing intravesical administration. A new pharmaceutical formulation including hrydrogel has been studied in an attempt to improve treatment administered by intravesical route. Permeation studies were made with the new formulation. Finally, an urothelial cancer cells culture has been developed and a viability test was performed with mitomycin C and BCG

Introdução: O carcinoma de células escamosas (CEC) do canal anal é uma neoplasia pouco frequente, correspondendo a 1-5% dos tumores intestinais. Entretanto, o risco de CEC do canal anal vem crescendo. O tratamento padrão do CEC de canal anal nos estádios II-III consiste em 5-fluorouracil infusional associado a mitomicina-C e radioterapia, desde 1974. Estudos clínicos com o objetivo de identificar novos esquemas terapêuticos mais convenientes para câncer do canal anal devem continuar. Métodos: Pacientes com CEC de canal anal T2-4N0M0 ou T (qualquer) N1-3M0, com bom performance clínico, função renal e hematológica normais foram tratados com capecitabina 825 mg/m2 12/12 horas durante a radioterapia associada a dose única de mitomicina-C 15 mg/m2 no Dia 1. O objetivo primário do estudo foi determinar a taxa de controle local em 6 meses da associação de capecitabina, mitomicina-C e radioterapia em pacientes com câncer do canal anal. Os objetivos secundários foram determinar a taxa de toxicidade aguda graus 3-4, conforme os critérios da CTCaev4.0, taxa de resposta completa 6 semanas após término da quimio-radioterapia, sobrevida global e livre de progressão e taxa de colostomia em 1 ano. O tamanho da amostra foi calculado usando a ferramenta \"estágio único de Fleming\". Considerando 85% de eventos esperados (taxa de controle local em 6 meses), 1 desvio padrão e 5% de erro alfa, o tamanho ideal da amostra foi de 51 pacientes. Resultados: De novembro/2010 a fevereiro/2014, 51 pacientes foram incluídos, sendo avaliados 43 pacientes. Dezessete pacientes (39,5%) tinham estádio II, 11 (25,6%) estádio IIIA e 15 (34,9%) estádio IIIB. O seguimento mediano foi de 23,1 meses. Entre os pacientes que foram avaliados em 6 meses, 3 (7%) apresentaram resposta clínica parcial, 37 (86%) tiveram resposta clínica completa e 3 (7%) apresentaram progressão de doença. O controle loco-regional em 6 meses foi de 86%. Em relação às toxicidades graus 3-4, observaram-se diarreia grau 3, em 4,6% dos pacientes, radiodermite grau 3, em 23,2%, vômitos grau 3, em 2,3%, plaquetopenia graus 3-4, em 6,9%, leucopenia grau 3, em 6,9%, e linfopenia grau 3, em 11,6%. Um paciente HIV positivo (2,3%) apresentou choque séptico grau 4, pneumonia grau 4, meningoencefalite herpética grau 4 e síndrome de ativação macrofágica grau 4. A taxa de colostomia foi de 18,6%. Conclusão: Capecitabina e mitomicina-C são um tratamento bem tolerado em pacientes com carcinoma de canal anal, com controle loco-regional em 6 meses em 86% dos pacientes. Palavras-chave: carcinoma de células escamosas, câncer anal, capecitabina, radioterapia, mitomicina-c / Background: Squamous cell carcinoma (SCC) of the anal canal is an uncommon malignancy accounting for 1-5% of intestinal tumors; however, its incidence has been increasing. Treatment for stage II and III anal canal SCC is infusional 5-fluorouracil associated with mitomycin and radiotherapy, since 1974. More convenient treatments for patients are needed. Methods: Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status, normal blood, and renal function were treated with capecitabine 825 mg/m2 bid during radiotherapy associated with a single dose of mitomycin 15 mg/m2 on day 1. Primary objective was local control rate at 6 months determined by clinical examination and radiological assessment. Sample size was calculated using Fleming single stage design. Results: From november/2010 to february/2014 51 patients were initially included, however 43 patients were assessed. Seventeen patients (39.5%) were stage II, 11 patients (25.6%) stage IIIA, and 15 patients (34.9%) stage IIIB. Four patients (9.3%) were HIV-positive, while 39 (90.7%) were HIV-negative. Median follow-up was 23.1 months. Among patients who finished the treatment and were reevaluated at 6 months 3 patients (7%) presented partial response, 37 patients (86%) had complete response, and 3 patients developed progression of the disease (7%). Regarding grade 3-4 toxicities, 10 patients (23.2%) had grade 3 radiodermitis, 3 patients (6.9%) had grade 3-4 thrombocytopenia, 5 (11.6%) had grade 3 lymphopenia, 1 patient (2.3%) had grade 3 vomiting, 2 patients (4.6%) had grade 3 diarrhea and 3 patients (6.9%) had grade 3 leukopenia. One HIV+ patient had septic shock, pneumonia, herpetic encephalitis and macrophage activation syndrome. Colostomy rate was 18.6%. Conclusions: Capecitabine and mitomycin with radiotherapy seem to be a safe treatment for SCC of the anal cancer, with a complete response rate in 6 months of 86%

Desde o início de 1990, a enxertia de gordura na prega vocal é descrita como um método para reparar a insuficiência glótica. O objetivo deste estudo é avaliar os efeitos da aplicação tópica de mitomicina-C no processo cicatricial de enxertos autólogos de gorduras inseridos em pregas vocais de coelhos através da medida da deposição de colágeno. Vinte e oito coelhos foram submetidos a enxertia de gordura em ambas pregas vocais. As pregas vocais direitas recebeu previamente a aplicação tópica de mitomicina-C (0,4mg/ml) durante cinco minutos enquanto que as pregas vocais esquerdas formavam o grupo controle (sem mitomicina-C). Quatro grupos com 6 coelhos cada foram sacrificados com 7, 14, 30 e 90 dias após a cirurgia de enxertia. As pregas vocais foram removidas para estudo histológico com a intenção de quantificar a deposição de colágeno através da coloração por Picrossírius Red sob microscopia polarizada. A deposição de colágeno foi menor em todos os grupos de pregas vocais que receberam aplicação tópica de mitomicina-C quando comparada com as pregas vocais do grupo controle. No presente estudo, a aplicação tópica de mitomicina-C antes da enxertia de gordura reduziu significativamente a deposição de colágeno (p = 0,05). / Since the early 1990s, fat implantation in the vocal fold is described as a method of repairing glottal insufficiency. The aim of this study was to evaluate the effect of topical application of mitomycin in the healing process with collagen deposition measurement around of autologous fat implants inserted in rabbits vocal folds. Twenty-eight rabbits were submitted to a fat implant in the both vocal folds. The right vocal folds received previously topical application of mitomycin (0,4mg/ml) for five minutes and the left vocal folds were the control group (without mitomycin). Four groups of 6 rabbits each were sacrificed 7, 14, 30 and 90 days after the implantation. The samples of the vocal folds were collected for histological analysis with the purpose of quantifying the collagen deposition by Picrosirius Red stain under polarization microscopy. The collagen deposition was lower in all groups of vocal folds with topical application of mitomycin than in control groups. In the present study, the topical application of mitomycin before the fat grafts reduced significantly the collagen deposition (p = 0,05).

Introdução: O carcinoma de células escamosas (CEC) do canal anal é uma neoplasia pouco frequente, correspondendo a 1-5% dos tumores intestinais. Entretanto, o risco de CEC do canal anal vem crescendo. O tratamento padrão do CEC de canal anal nos estádios II-III consiste em 5-fluorouracil infusional associado a mitomicina-C e radioterapia, desde 1974. Estudos clínicos com o objetivo de identificar novos esquemas terapêuticos mais convenientes para câncer do canal anal devem continuar. Métodos: Pacientes com CEC de canal anal T2-4N0M0 ou T (qualquer) N1-3M0, com bom performance clínico, função renal e hematológica normais foram tratados com capecitabina 825 mg/m2 12/12 horas durante a radioterapia associada a dose única de mitomicina-C 15 mg/m2 no Dia 1. O objetivo primário do estudo foi determinar a taxa de controle local em 6 meses da associação de capecitabina, mitomicina-C e radioterapia em pacientes com câncer do canal anal. Os objetivos secundários foram determinar a taxa de toxicidade aguda graus 3-4, conforme os critérios da CTCaev4.0, taxa de resposta completa 6 semanas após término da quimio-radioterapia, sobrevida global e livre de progressão e taxa de colostomia em 1 ano. O tamanho da amostra foi calculado usando a ferramenta \"estágio único de Fleming\". Considerando 85% de eventos esperados (taxa de controle local em 6 meses), 1 desvio padrão e 5% de erro alfa, o tamanho ideal da amostra foi de 51 pacientes. Resultados: De novembro/2010 a fevereiro/2014, 51 pacientes foram incluídos, sendo avaliados 43 pacientes. Dezessete pacientes (39,5%) tinham estádio II, 11 (25,6%) estádio IIIA e 15 (34,9%) estádio IIIB. O seguimento mediano foi de 23,1 meses. Entre os pacientes que foram avaliados em 6 meses, 3 (7%) apresentaram resposta clínica parcial, 37 (86%) tiveram resposta clínica completa e 3 (7%) apresentaram progressão de doença. O controle loco-regional em 6 meses foi de 86%. Em relação às toxicidades graus 3-4, observaram-se diarreia grau 3, em 4,6% dos pacientes, radiodermite grau 3, em 23,2%, vômitos grau 3, em 2,3%, plaquetopenia graus 3-4, em 6,9%, leucopenia grau 3, em 6,9%, e linfopenia grau 3, em 11,6%. Um paciente HIV positivo (2,3%) apresentou choque séptico grau 4, pneumonia grau 4, meningoencefalite herpética grau 4 e síndrome de ativação macrofágica grau 4. A taxa de colostomia foi de 18,6%. Conclusão: Capecitabina e mitomicina-C são um tratamento bem tolerado em pacientes com carcinoma de canal anal, com controle loco-regional em 6 meses em 86% dos pacientes. Palavras-chave: carcinoma de células escamosas, câncer anal, capecitabina, radioterapia, mitomicina-c / Background: Squamous cell carcinoma (SCC) of the anal canal is an uncommon malignancy accounting for 1-5% of intestinal tumors; however, its incidence has been increasing. Treatment for stage II and III anal canal SCC is infusional 5-fluorouracil associated with mitomycin and radiotherapy, since 1974. More convenient treatments for patients are needed. Methods: Patients with SCC of anal cancer T2-4N0M0 or T (any) N1-3M0, with good performance status, normal blood, and renal function were treated with capecitabine 825 mg/m2 bid during radiotherapy associated with a single dose of mitomycin 15 mg/m2 on day 1. Primary objective was local control rate at 6 months determined by clinical examination and radiological assessment. Sample size was calculated using Fleming single stage design. Results: From november/2010 to february/2014 51 patients were initially included, however 43 patients were assessed. Seventeen patients (39.5%) were stage II, 11 patients (25.6%) stage IIIA, and 15 patients (34.9%) stage IIIB. Four patients (9.3%) were HIV-positive, while 39 (90.7%) were HIV-negative. Median follow-up was 23.1 months. Among patients who finished the treatment and were reevaluated at 6 months 3 patients (7%) presented partial response, 37 patients (86%) had complete response, and 3 patients developed progression of the disease (7%). Regarding grade 3-4 toxicities, 10 patients (23.2%) had grade 3 radiodermitis, 3 patients (6.9%) had grade 3-4 thrombocytopenia, 5 (11.6%) had grade 3 lymphopenia, 1 patient (2.3%) had grade 3 vomiting, 2 patients (4.6%) had grade 3 diarrhea and 3 patients (6.9%) had grade 3 leukopenia. One HIV+ patient had septic shock, pneumonia, herpetic encephalitis and macrophage activation syndrome. Colostomy rate was 18.6%. Conclusions: Capecitabine and mitomycin with radiotherapy seem to be a safe treatment for SCC of the anal cancer, with a complete response rate in 6 months of 86%

Desde o início de 1990, a enxertia de gordura na prega vocal é descrita como um método para reparar a insuficiência glótica. O objetivo deste estudo é avaliar os efeitos da aplicação tópica de mitomicina-C no processo cicatricial de enxertos autólogos de gorduras inseridos em pregas vocais de coelhos através da medida da deposição de colágeno. Vinte e oito coelhos foram submetidos a enxertia de gordura em ambas pregas vocais. As pregas vocais direitas recebeu previamente a aplicação tópica de mitomicina-C (0,4mg/ml) durante cinco minutos enquanto que as pregas vocais esquerdas formavam o grupo controle (sem mitomicina-C). Quatro grupos com 6 coelhos cada foram sacrificados com 7, 14, 30 e 90 dias após a cirurgia de enxertia. As pregas vocais foram removidas para estudo histológico com a intenção de quantificar a deposição de colágeno através da coloração por Picrossírius Red sob microscopia polarizada. A deposição de colágeno foi menor em todos os grupos de pregas vocais que receberam aplicação tópica de mitomicina-C quando comparada com as pregas vocais do grupo controle. No presente estudo, a aplicação tópica de mitomicina-C antes da enxertia de gordura reduziu significativamente a deposição de colágeno (p = 0,05). / Since the early 1990s, fat implantation in the vocal fold is described as a method of repairing glottal insufficiency. The aim of this study was to evaluate the effect of topical application of mitomycin in the healing process with collagen deposition measurement around of autologous fat implants inserted in rabbits vocal folds. Twenty-eight rabbits were submitted to a fat implant in the both vocal folds. The right vocal folds received previously topical application of mitomycin (0,4mg/ml) for five minutes and the left vocal folds were the control group (without mitomycin). Four groups of 6 rabbits each were sacrificed 7, 14, 30 and 90 days after the implantation. The samples of the vocal folds were collected for histological analysis with the purpose of quantifying the collagen deposition by Picrosirius Red stain under polarization microscopy. The collagen deposition was lower in all groups of vocal folds with topical application of mitomycin than in control groups. In the present study, the topical application of mitomycin before the fat grafts reduced significantly the collagen deposition (p = 0,05).